Molecular Diagnostics for Cancer Drug Development
Conference - Cambridge, MA, United States
Improve biomarker discovery, reduce clinical bottlenecks and advance your MDx capabilities
5th annual Molecular Dx for Cancer Drug Development: Key insights to optimize MDx strategies and develop more powerful, personalized cancer treatments
Lack of relevant predictive biomarkers, tissue sample shortages, uncertainty over effective trial design and execution…the right commercial strategy could prove meaningless if these clinical challenges are not successfully overcome.
In order to get better, more effective cancer treatments to patients faster, the need for a comprehensive, end-to-end strategy for MDx success has never been more prominent.
Now in its 5th year, Molecular Dx: Cancer Drug Development is the must-attend forum for navigating the biomarker-driven oncology drug development space.
Why is it the must attend forum? Because Molecular Dx gives you the tools to not only enhance your existing biomarker discovery and validation strategies, but also provides you with cutting edge updates and advanced applications to take your MDx programs further.
(Courtesy of Hyatt Regency Cambridge, commons.wikipedia.org)
Molecular Diagnostics for Cancer Drug Development
Tue, Jun 18, 2013 - Thu, Jun 20, 2013
Hyatt Regency Cambridge
575 Memorial Drive, Cambridge, MA 02139, USA
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
